Corporate Rebranding

Forte Group is rebranding to Vanta Holdings (VANTA), pending CSE approval, to unify its beverage and nutraceutical offerings under a premium brand. The company will transition its TRACE product line to VANTA, fortifying brand continuity. Initial shipments to China are anticipated in December 2025, fulfilling modified purchase orders of $2.5 million. Vanta plans U.S. market entry via direct-to-consumer e-commerce for its nutraceuticals. A new CUSIP and ISIN will be obtained and disclosed.

Algernon Pharmaceuticals (AGNPF) shareholders approved a new Series 1 Preferred Share class with a 10% annual dividend and convertibility into common shares. Following approval, the company will issue preferred shares and warrants related to past transactions. All board nominees were elected with over 95% approval. Algernon plans to rebrand as Algernon Health Inc., expanding into Alzheimer’s Disease diagnostics and neuroimaging clinics across North America, representing a strategic shift to diversify revenue streams.